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Summary: The performance characteristics of four radioisotopically and non-radioisotopically labelled two-site
immunoassays for the determination of 'intact' parathyrin in plasma samples are reported.
Within-run as well as between-assay imprecision was characterized by coefficients of variation usually < 10%.
Assessment of the linearity of dilution in plasma samples from patients with severe secondary hyperparathyroidism
(obtained from patients with chronic renal failure prior to dialysis) revealed that an assay with N-terminal capture
antibodies showed an increase of the values after dilution (p < 0.05) whereas another assay with C-terminal capture
antibodies was characterized by a decrease of the values after dilution (p < 0.05).
Correlation between the data obtained by the four assays and our currently used routine method (N-tact® PTH from
INCSTAR) revealed correlation coefficients of r > + 0.96 and slope values between 0.83 and 1.34.
Determination of the analytical recovery of parathyrin (1—84) from two reference materials [First International
Reference Preparation 79/500 and synthetic human parathyrin (1—84)] revealed that the recovery rates were strongly
influenced by (a) the assay employed for determination of parathyrin concentrations, (b) the matrix of the diluent
and (c) the reference material used. These results as well as systematic differences between the assays we examined
(employing plasma samples from unselected nephrological patients) require further efforts towards a more rigorous
standardization of 'intact' parathyrin assays.
Introduction (b) discordant results and
Parathyrin, which regulates the calcium ion concentra- (c) reduced clearance of immunoreactive C-terminal
tions in extracellular body fluids, is a single polypeptide parathyrin-fragments in patients with renal insufficiency
chain consisting of 84 amino acids (MT = 9425). The due to its longer biological half-life as compared with
hormone is metabolized within the parathyroid glands as the 'intact' molecule (2).
well as by other organs (e. g. liver and kidney) with the
 To overcome these disadvantages methods have been
cleavage site in the 33-41 amino acid region yielding
 developed in recent years for spedfic determination of
N-terminal and C-terminal parathyrin fragments (for re-
 parathyrin (1 _84) Cintact parathyrirO. 7^ include
view see I.e. (1)).
(a) assays employing antisera against parathyrin
Radiqimmunoassays based upon antisera with specific- (24-48) (i. e. the proteolytic region of parathyrin) (2),
ity for these fragments were characterized by the
following disadvantages: (W secluential extraction of N-terminal immunoreactiv-
ity with subsequent midregion(44—68)-specific radio-
(a) clinically unacceptable lower detection limit, immunoassay (3) and
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(c) two-site immunometric assays employing two dif-
ferent antibodies (either monoclon^J or polyclonal) with
N-terminal as well as midregion/C-terminal specificity
(4-9). Here we report on the performance characteris-
tics of different radioisotopically and non-radioisotopi-
cally labelled immunometric assays for specific determi-
nation of 'intact' parathyrin with special regard to sam-
ples from unselected nephrological patients.
Materials and Methods
Samples
Venous blood specimens (taken between 8 and 9 a. m. and antico-
agulated with the dipotassium salt of ethylenediaminetetraacetic
acid) were obtained from unselected nephrological patients. The
plasma fractions were separated from the blood cells within one
hour after specimen collection. In order to avoid repeated freeze-
thaw cycles at least two aliquots from each plasma sample were
stored at -20 °C (for a period of up to 6 months). All analyses
were performed immediately after thawing at + 4 °C.
Methods for determination of human parathyrin
(1-84)
Four methods for specific determination of human parathyrin
(1—84) concentrations were examined:
Method A
Immulite® Intact PTH (DPC® Diagnostic Products Corporation,
Los Angeles, CA, U.S.A.)
Method
PTH-EASIA (no. 4014800; Medgenix Diagnostics S A, Fleurus,
Belgium)
Method C
Intact-PTH-IRMA (no. 11041; Immuno Biological Laboratories,
Hamburg, Germany)
Method D
Gamma BCT Intact PTH IRMA (no. AA-52F1; Immunodiagnostic
Systems, Boldon, U.K.)
For method comparisons, the procedure we currently use for deter-
mination of parathyrin (1-84) was employed (N-tact® PTH; no.
22800; INCSTAR Corporation, Stillwater, MM, U. S. A.) (reference
interval [2.5th-97.5th percentile; age-range: 20-60 years]: 1.1-
5.8 pmol/1).
All kits examined are heterogeneous immunoassays of the immu-
nometric type and were manually performed in duplicates accord-
ing to the manufacturer's recommendations.
Calibration of kit A is based upon a lot-specific 'master curve'
(as assessed by the manufacturer) with a re-calibration procedure
repeated every two weeks employing 'Intact PTH Adjusters (low/
high)'. Calibration of kit B was performed by linear interpolation
between the plotted analytical results of the standards using Beh-
ring ELISA processor III (Behringwerke AG, Marburg, Germany).
For kits C and D, respectively, a standard curve was constructed
by a 'smoothed spline' algorithm (using a 1470 Wallac Wizard™
Gamma Counter).
More details concerning the kits are listed in table 1.
Reference materials
The following reference materials were employed:
(a) First International Reference Preparation of Parathyroid Hor-
mone, Human, for Immunoassay (1st IRP 79/500; National Insti-
pe
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Tab. 2 Within-run imprecision of the paruthyrin (1-84) methods
examined (n = 10).
Method
Λ
Β
C
D
Mean
[pmol/1]
3,8
86.1
3.9
85.0
2.8
19.7
4.6
49.2
Standard
deviation
[pmol/1]
0.20
5.51
0.35
3.16
0.20
0,39
0.23
2.03
Coefficient
of variation
i.%]
5.3
6.4
9.0
3.7
7.1
2.0
5.0
4.1
Tab. 3 Between-day imprecision of (he parathyrin (1-84) meth-
ods examined (n = K).
Method1
Λ
B
C
D
Mean
[pmol/1]
4.8
45.0
3.1
39.7
2.9
20.8
3.2
16.3
Standard
deviation
[pmoiyil
0.33
5.44
0.43
3.24
0.19
0.81
0.30
1.98
Coefficient
of variation
[%]
6.9
12.1
13.9
8.2
6.6
3.9
9.4
12.1
1
 For assessment of between-day imprecision the cjuality control
materials of the respective kits were used.
lute for Biological Standards and Control, London, U.K.) (as-
signed ampoule content: 0.1 lU/ampoule [corresponding to approx-
imately 10 pmol parathyrin]) (purity > 95%) (10).
(h) Synthetic parathyrin (1-84) (human) (purity as assessed by
HPLC > 99%) (no. 11-1370; lot no. 504782; Bachern Feinchcmika-
licn AC, Buhendorf, Switzerland) (assigned vial content: 0.5 mg
parathyrin). Both reference materials are claimed to be free of para-
thyrin fragments by HPLC analysis.
S t a t i s t i c a l Methods
The statistical methods employed include the Passing & Bahlok
( I I ) procedure for method comparison studies as well as Frlud-
man's test (employing the software package SPSS/PC + V2.0) for
assessing differences between the parathyrin values at different di-
lution steps.
L i n e a r i t y o f d i l u t i o n
Linearity of dilution was investigated using plasma sam-
ples from patients with chronic renal failure and severe
secondary hyperparathyroidism, immediately before di-
alysis (range of parathyrin values: 59—206 pmol/1) em-
ploying the following diluents:
(a) Paralhyrin-frcc 'sample diluent ' (component of the
Immulite® Intact PTH kit) (method A),
(b) the zero standards of the kits (method B and C) and
Results
I m p r e c i s i o n
Different human plasma pools were analysed 10 times
to assess within-run imprecision of methods A, B and
D, respectively. For method C 'controls 1 and 2' (com-
ponents of the kit) were used (tab. 2).
The results of between-day imprecision arc shown in
table 3.
Lower l i m i t of detection
Twenty replicate analyses were made within a single
run employing
(a) the zero standards of the kits (methods B and C),
(b) parathyrin-free 'sample diluent' (component of the
Immulitc® Intact PTH kit) (method A and D),
The lower limit of detection, defined as the concentra-
tion corresponding to the 95% confidence interval of
counts/absorbance, was found to be 0.1 pmol/1 (methods
A and B) and 0.2 pmol/1 (methods C and D).
0.4
1:2 1:4
Dilution
1:8
Fig. 1 Linearity of dilution
Plasma samples (from patients with chronic renal failure and se-
vere secondary hyperparathyroidism. immediately before dialysis)
were mixed with different parathyrin-free diluents (for further de-
tails see under Results).
Different plasma samples wore used for assays A—D.
The fractious recovered after correction for dilution were given as
means ± Sl;M,
Assay A = dots (n « 5); assay B = circles (n « 5); assay C ~
crosses (n « 3); assay D = squares (n = 4),
nur J Clin Chcm Clin Biochem 1995; 33 (No 5)
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(c) pooled serum after accelerated thermal degradation
of parathyrin (parathyrin concentration < 0.1 pmol/1 as
assessed by the N-tact® PTH kit) (method D).
After correcting for the dilution factor and expressing
the values as a fraction of the concentrations measured
in the undiluted sample, the recovery rates (at a 1 : 8
dilution) ranged from 71 ± 5% (method C) to 122 ± 7%
(method B) (mean ± SEM). For method B the values
obtained in the diluted samples significantly increased
compared with those in the undiluted samples
(p < 0.05) whereas for method C the values obtained in
the diluted samples significantly decreased (p < 0.05).
For further details see figure 1.
Method comparison
Comparisons were made between methods -D and
N-tact® PTH (see Materials and Methods). The rela-
tionship between the values was characterized by lin-
ear regression coefficients between 4- 0.968 and
+ 0.987 (fig. 2).
Analytical recovery of parathyrin (1-84)
from reference materials dissolved in
different diluents
Lyophilized parathyrin preparations (1st International
Reference Preparation 79/500 as well as synthetic hu-
man parathyrin (1—84)) were re-solubilized with a
buffer solution (10 mmol/1 sodium phosphate, pH 7.2,
with 120 mmol/1 NaCl and 2g/l human albumin)
yielding stock solutions of 2500 pmol/1 [1st Interna-
tional Reference Preparation] and 2630 pmol/1 [syn-
thetic parathyrin (1-84) (human), respectively]. Stock
aliquots were stored at -20 °C for no longer than 2
weeks. Immediately after thawing at + 4 °C stock ali-
quots were diluted 1:10, 1 :20, 1 :40, 1 : 80, respec-
tively, with
140
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B
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Parathyrin (N-tact PTH) [pmol/l]
00
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Fig. 2 Method comparison between methods -D and N-tact® PTH (INCSTAR Corporation).
The following regression equations according to Passing & Bablok (11) were obtained:
Parathyrin [pmol/1] (method A) Parathyrin [pmol/1] (method C)
= -1.00* + 1.32* X parathyrin (N-tact® PTH) [pmol/1] = -0.27* + 1.04* X parathyrin (N-tact® PTH) [pmol/l]
(r = + 0.962; n = 394) (r = -H 0.987; n = 255)
Parathyrin [pmol/1] (method B) Parathyrin [pmol/1] (method D)
= + 0.01 + 1.34* X parathyrin (N-tact® PTH) [pmol/1] = -0.54* + 0.83* X parathyrin (N-tact® PTH) [pmol/1]
(r = + 0.968; n = 277) (r = + 0.971; n = 279)
* significant deviation (p < 0.05) from 0 (y-intercept) and 1 (slope) according to Passing & Bablok (11).
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(a) the zero standards of the methods employed,
(b) pooled serum after accelerated thermal degradation
of parathyrin (parathyrin concentration <0.1 pmol/1
as assessed by the N-tact® PTH kit) and
(c) parathyrin-free 'sample diluent' (component of the
Immulite® Intact PTH kit).
There was a strong dependence of the recovery rates
upon
(a) the reference material used,
(b) the diluent and
(c) the method employed for determination of para-
thyrin (1-84) (tab. 4).
Discussion
Determination of the analytical recovery of parathyrin
(1—84) from reference materials resulted in recovery
rates of between 6% (!) and 75%. There is a marked
dependence of the values obtained upon
(a) the matrix of the diluent,
(b) the reference preparations used and
(c) the assay employed.
A lower immunoreactivity of the First International
Reference Preparation (No. 79/500) yielding recovery
rates between 44% (4) and 60% (12) of those values
obtained with chemically synthesized parathyrin
(1 — 84) has already been described.
For the interpretation of the recovery rates of para-
thyrin (1 — 84) from the reference materials it has to
be taken into account that
(a) the First International Reference Preparation 797
500 has not been chemically characterized and is
therefore not suitable as a chemical standard but only
for calibrating working standards for parathyrin
immunoassays (10),
(b) the mass content of the ampoules coded 79/500
is based upon indirect estimates and claimed to be
"approximately 10 pmol" (10) and
(c) no data are so far available regarding the immuno-
reactivity of the synthetic parathyrin (1—84) prepara-
tion employed.
Tab. 4 Analytical recovery of parathyrin (1-84) from reference materials dissolved in different
diluents.
Method
A
B
Reference materials
1st International Reference
Preparation
Synthetic human parathyrin
(1-84)
1st International Reference
Preparation
Synthetic parathyrin
Diluent* Measured Recovery
parathyrin rateb
concentration6
[pmol/I] [%]
Parathyrin-free 82
'sample diluent'
Parathyrin-free 197
'sample diluent'
'Zero' standard 40
Parathyrin-free 1 1 1
33
75
16
42
Recovery rate
at further
dilution steps0
31 ±2
69 ± 1
17 ±2
42 ± 1
(1-84)
1st International Reference
Preparation
serum
'Zero' standard 14 5± 1
Synthetic human parathyrin
(1-84)
D 1st International Reference
Preparation
Synthetic human parathyrin
(1-84)
'Zero' standard 74
Parathyrin-free 125
• serum
Parathyrin-free 30
serum
Parathyrin-free 72
serum
28 20 ± 1
48 43 ± 2
12 11 ±1
27 25 ± 1
a
 See Results for characterization of 'diluents*. c
 i. e. at 1 :20, I : 40 and 1 : 80 dilution of stock aliquots (see
b
 At 1 : 10 dilution of stock aliquots corresponding to a calculated above); means ± standard deviations of the recovery rates at these
concentration of 250 pmol/1 [1st International Reference Prepara- three dilution steps are given,
tion 79/500] and 263 pmol/1 [synthetic human parathyrin (1-84)];
for assessment of recovery rates the calculated concentrations were
set as 100%.
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For the following reasons a loss of the polypeptide
by surface adsorption or a degradation seems to be im-
probable:
(a) human albumin (free of protease activity) was
added to the buffer solution used for reconstitution of
the lyophilized parathyrin preparations (13); the Na-
tional Institute for Biological Standards and Control
claimed that a concentration of 2 g/1 albumin in the
buffer solution used for re-constitution of the reference
preparation is sufficient (13);
(b) the re-solubilized reference materials were pro-
cessed under optimal temperature conditions;
(c) the pH value in the buffer solution used for re-
constitution was 7.4. Schmidt-Gayk et al. (14) prepared
a similar standard solution of parathyrin (1-84) in a
buffer solution adjusted to pH 7.4. The National Insti-
tute for Biological Standards and Control recommends
a pH value of 8.6 (13).
The systematic differences between the methods we
examined when using patient samples may be ex-
plained by the different specificity of the antibodies
or differing assignments of standards against the refer-
ence preparations used by the manufacturers (5).
In patients with chronic renal insufficiency 'intact'
parathyrin assays may be prone to a significantly
negative interference by an excess of C-terminal frag-
ments saturating the C-terminal capture antibodies (15,
16). All samples used to assess the linearity of dilution
were obtained from patients with chronic renal failure
and severe secondary hyperparathyroidism, immedi-
ately before dialysis. In these samples excessively
increased concentrations of C-terminal parathyrin im-
munoreactivity can be observed (16). However, none
of the methods examined in the present study with a
C-terminal antibody attached to the solid phase (assays
A and C) showed an increase of'fhe recovery rates.
On the contrary for method B (a two-step-assay with
N-termiiial capture antibodies) the values obtained in
the diluted samples significantly increased compared
with those in the undiluted samples (p < 0.05).
Within-run as well as between-assay imprecision was
characterized by coefficients of variation usually being
< 10%. This essentially corresponds to the values de-
scribed earlier for two-site immunometric assays of 'in-
tact' parathyrin (4-7).
Due to the highly significant correlation between the
values obtained with different methods all assays may
be equally useful for the diagnosis of secondary hyper-
parathyroidism in plasma samples from nephrological
patients. However, to further improve the comparability
of the values obtained with different methods as well as
to minimize matrix effects efforts towards a more rigor-
ous standardization (concerning the specificity of the an-
tibodies as well as the assignment of the standards)
should be made.
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